Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Clinical Trial Failure May Be Counteracted by Biomarkers in the Future

By BiotechDaily International staff writers
Posted on 25 Dec 2012
Biomarkers could someday decrease the amount of failed clinical trials, if fully supported by the medical community, according to new market research.

The new report, published by healthcare market research company GBI Research (New York, NY, USA), noted that biomarkers can be utilized in all phases of drug discovery to determine the safety and effectiveness of candidate drugs. They are able to identify a number of lead candidates and drug targets, while predicting which drugs will not work, saving drug discovery costs and research time in the early stages of development.

With surging drug attrition rates, the proportion of drugs gaining regulatory approval has been reduced to only 8%, and most failures during the drug discovery process happen in the late clinical trial stages, leading to a considerable loss of money, time, and effort and patients are left untreated. The year 2007 saw the fewest drug approvals since 1983, alarming the pharmaceuticals sector and creating a demand for drug discovery techniques that can more effectively predict failures.

Biomarkers have several benefits over traditional drug discovery approaches--for example, they are highly sensitive and selective in their approach, and their application in drug discovery makes the process robust and time-efficient.

However, in spite of benefits of biomarkers over conventional methods, most pharmaceutical companies, academic institutions, and clinical practitioners do not use them extensively in drug discovery due to a lack of awareness among the academic community. Although essential research data are available, there is a scarcity of intelligent and novel technologic developments such as technology systems and biomarker assays, and this is restraining growth of the global biomarkers market.

Funding problems also pose a challenge for the necessary R&D of biomarkers. The development process of biomarkers requires strong technical expertise and the combination of genomic, proteomic, and transcriptomics-based technologies, which are very expensive and require huge funding. However, many funding organizations require strong clinical data and validation to provide funds for research and testing phases, and the initial gathering of data itself requires funding, thereby forming a vicious circle. The biomarker discovery and confirmation procedure is also long and burdensome, with only 1% of all biomarkers found reaching the validation stage.

Until the profile of biomarkers is adequately increased, and enough money is invested, the pharmaceutical industry will not see the benefits of biomarkers in action, in spite of the billion-dollar clinical trial industry they could potentially transform.

GBI Research is a provider of business intelligence reports, providing actionable data and forecasts based on the insights of industry leaders.

Related Links:

GBI Research



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.